Gary J. Bridger
Scientific Advisory Board
Synthetic Organic Chemistry
Alectos Therapeutics
Canada
Biography
Dr. Bridger completed his PhD in synthetic organic chemistry at the University of Manchester Institute of Science and Technology (UK) and subsequently completed a post-doctoral fellowship at Boston College. Dr Bridger worked at Johnson Matthey, aiding the development of Atiprimod, currently in clinical trials at Callisto Pharmaceuticals. Dr Bridger co-founded AnorMED Inc. and served as Vice President of Research and Development and Chief Scientific Officer. He was responsible for research, development, and clinical programs within AnorMED; a leading company in the development of chemokine receptor inhibitors for a variety of disease applications. He was responsible for the development of AMD3100 (plerixafor, Mozobilâ„¢), a new stem cell mobilizing agent for treatment of multiple myeloma and non-hodgkins lymphoma patients, including the design and completion of two randomized Phase 3 clinical trials. In late 2006, AnorMED was acquired by Genzyme for US $600 million and Mozobil was approved by the US FDA in 2008. In June 2010, Dr. Bridger became a Ventures Partner at Ventures West, an active venture capital partner that invests in early stage technology companies. Dr. Bridger is named inventor on 34 granted US patents and is an author of more than 80 scientific publications.
Research Interest
Synthetic Organic Chemistry
